178 related articles for article (PubMed ID: 33016133)
21. The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study.
Ohe Y; Yamazaki N; Yamamoto N; Murakami H; Yoh K; Kitano S; Hashimoto H; Murayama A; Nakane S; Gemma A
Jpn J Clin Oncol; 2022 May; 52(6):623-632. PubMed ID: 35325169
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of Injection of Xuesaitong (lyophilized) in 30097 cases in real world].
Xin-Yao J; Ke-Yi W; Jing-Bo Z; Chun-Xiang L; Hui W; Zhi L; Wen-Tai P; Hu-Cheng W; Nan LI; Hui-Zi C; Jun-Hua Z; Wen-Ke Z
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):5024-5028. PubMed ID: 33350278
[TBL] [Abstract][Full Text] [Related]
23. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
24. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
25. Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations.
Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Zhu JH
Drug Des Devel Ther; 2018; 12():757-767. PubMed ID: 29670332
[TBL] [Abstract][Full Text] [Related]
26. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
Wang LX; Xie YM; Ai QH; Xu WF
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
[TBL] [Abstract][Full Text] [Related]
27. [Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2786-8. PubMed ID: 22292365
[TBL] [Abstract][Full Text] [Related]
28. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
Endrikat J; Schwenke C; Prince MR
Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
[TBL] [Abstract][Full Text] [Related]
29. Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis.
Zhang X; Wu J; Zhang B
BMC Complement Altern Med; 2015 Feb; 15():36. PubMed ID: 25888429
[TBL] [Abstract][Full Text] [Related]
30. [Protocol of intensive hospital monitoring with long follow up and large sample: Diemailing Kudiezi injection as example].
Liao X; Xie YM; Wang GQ
Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4494-4499. PubMed ID: 28936829
[TBL] [Abstract][Full Text] [Related]
31. Compatible stability study of panax notoginseng saponin injection (xueshuantong®) in combination with 47 different injectables.
Wang M; Zhang H; Dong R; Tan L; Liu Z; Zhu Y; Gao X; Ren X
Biomed Chromatogr; 2016 Oct; 30(10):1599-610. PubMed ID: 27037605
[TBL] [Abstract][Full Text] [Related]
32. Post-marketing safety surveillance and reevaluation of Motherwort injection: A clinical study of 10 094 cases.
Cao Shan DOSOGC; Zhang W; Zhao Z; Heng M; Bu H; Wang H; Liu X; Wang Z; Cai Y; Ma Y; Cui Shihong DOO; Deng J; Yang Y; Ding G; Ding Y; Dong L; Duan Z; Fan L; Fan Y; Fu F; He J; Ji S; Jin L; Li H; Li H; Liao T; Lu W; Luo X; Lü Z; Ma F; Ma D; Shi T; Sun J; Teng H; Wang J; Wang R; Wang Y; Wang Z; Xi J; Xu M; Xu Z; Yan Q; Zhang G; Yang C; Yin J; Yu J; Yuan W; Zhang M; Zhao R; Zhong Y; Zhou J
J Tradit Chin Med; 2018 Aug; 38(4):625-635. PubMed ID: 32186089
[TBL] [Abstract][Full Text] [Related]
33. [Adverse drug reactions or adverse events of Chaihu Injection: a systematic review].
Kong XY; Hao Y; Wu TX; Xie YM
Zhong Xi Yi Jie He Xue Bao; 2010 Dec; 8(12):1124-32. PubMed ID: 21144455
[TBL] [Abstract][Full Text] [Related]
34. [Research progress of adverse reactions of traditional Chinese medicine injections].
Tan LJ; Wang M; Zhu Y
Zhongguo Zhong Yao Za Zhi; 2014 Oct; 39(20):3889-98. PubMed ID: 25751935
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of rational clinical uses of traditional Chinese medicine injections and factors influencing adverse drug reactions].
Sun SG; Li ZF; Xie YM; Liu J; Lu Y; Song YF; Han YH; Liu LD; Peng TT
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2969-73. PubMed ID: 24471313
[TBL] [Abstract][Full Text] [Related]
36. Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.
Yu Z; Huang R; Zhao L; Wang X; Shangguan X; Li W; Li M; Yin X; Zhang C; Liu D
Front Oncol; 2021; 11():757196. PubMed ID: 34745993
[TBL] [Abstract][Full Text] [Related]
37. [A postmarketing surveillance study on 31,724 patients using Dengzhan Xixin injection in hospital].
Li YY; Lei L; Xie YM
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4757-61. PubMed ID: 27245018
[TBL] [Abstract][Full Text] [Related]
38. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
Zhang W; Xie YM; Yu WY
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation on safety of puerarin injection in clinical use].
Xie XS; Dong YZ; Mu DP; Pan XL; Zhang FY
Zhongguo Zhong Yao Za Zhi; 2018 Oct; 43(19):3956-3961. PubMed ID: 30453723
[TBL] [Abstract][Full Text] [Related]
40. Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.
Kim CJ; Song R; Chen J; Tavares Da Silva F; Gopala KB; Kim JH; Bi D; Park JS
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):837-842. PubMed ID: 28266092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
